EMD Millipore Presents New Sustained-Release Excipient for Oral Dosage Forms

EMD Millipore, the life-science division of Merck KGaA, has introduced Parteck SRP 80, a new functional excipient for oral sustained-release formulations. The excipient is polyvinyl alcohol (PVA)-based and fully synthetic-according to EMD Millipore, this feature ensures batch-to-batch and performance consistency and facilitates quality by design (QbD) and validation processes.

Parteck SRP 80 is suitable for direct compression processes and enables fast, easy, and efficient formulation development as well as production processes. The excipient complies with the European Pharmacopoeia (Ph. Eur.), the United States Pharmacopoeia (USP), and the Japanese Pharmacopoeia Excipients (JPE). EMD Millipore says Parteck SRP 80 will be part of its Emprove program to facilitate regulatory filing and registration processes.

"Pharmaceutical excipients play an essential role in the development of safe and effective medicines," said Andrew Bulpin, executive vice-president of Process Solutions, EMD Millipore, in a press statement. "Parteck SRP 80 represents a new choice for customers looking to formulate prolonged-release oral dosage forms with reliable performance profiles as well as robust and cost efficient production processes, which can translate into improved patient safety and compliance."